Drug methylation in cancer therapy: lessons from the TPMT polymorphism
- 20 October 2003
- journal article
- review article
- Published by Springer Nature in Oncogene
- Vol. 22 (47) , 7403-7413
- https://doi.org/10.1038/sj.onc.1206944
Abstract
The genetic polymorphism of thiopurine methyltransferase (TPMT) is one of the most developed examples of pharmacogenetics, spanning from molecular genetics to clinical diagnostics for individualizing thiopurine therapy (i.e. azathioprine, mercaptopurine, and thioguanine). Elucidation of the molecular mechanisms and biochemical consequences of TPMT deficiency demonstrates how pharmacogenetic traits can be identified, characterized, and translated to the bedside. Insights gained from studies of the TPMT polymorphism illustrate the potential of pharmacogenomics to optimize cancer therapy by avoiding toxic side effects in genetically distinct subgroups of patients.Keywords
This publication has 67 references indexed in Scilit:
- Frequencies of thiopurine S‐methyltransferase mutant alleles (TPMT*2, *3A, *3B and *3C) in 151 healthy Japanese subjects and the inheritance of TPMT*3C in the family of a propositusBritish Journal of Clinical Pharmacology, 2001
- Demonstration of Thiopurine Methyltransferase Activity in the Erythrocytes of CatsJournal of Veterinary Internal Medicine, 2000
- Thiopurine Methyltransferase in Red Blood Cells of Dogs, Cats, and HorsesJournal of Veterinary Internal Medicine, 2000
- Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cellsPharmacogenetics, 1999
- Erythrocyte thiopurine methyltransferase activity in a Korean populationBritish Journal of Clinical Pharmacology, 1996
- Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipientThe Lancet, 1993
- Hypoxanthine‐guanine phosphoribosyl‐transferase in childhood leukemia: Relation with immunophenotype, in vitro drug resistance and clinical prognosisInternational Journal of Cancer, 1992
- Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemiaThe Journal of Pediatrics, 1991
- Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemiaThe Lancet, 1990
- Regulation of protein degradation rates in eukaryotesCurrent Opinion in Cell Biology, 1989